

# INCONTINENCE


### **EDITORS**

PAUL ABRAMS - LINDA CARDOZO - SAAD KHOURY - ALAN WEIN









4<sup>th</sup> International Consultation on Incontinence, Paris July 5-8, 2008

4th Edition 2009

## **Acknowledgement**

We would like to thank:

- The Bristol Urological Institute and
- The Urology Department at La Pitié Hospital in Paris and its chairman Professor F. Richard

for kindly providing logistic assistance for the editing of this book.

We would also like to thank all the contributors for their enthusiastic support and help.

#### For information and orders:

**Distributor: EDITIONS 21** 

76, rue de la Pompe - 75016 Paris - FRANCE

Fax: +33 1 45 04 72 89 E-mail: editions21@wanadoo.fr

#### © Health Publication Ltd 2009

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without prior permission of the publisher.

Accurate indications, adverse reactions, and dosage schedules for drugs are provided in this book, but it is possible that they may change. The reader is urged to review the package information data of the manufacturers of the medications mentioned.

The Publishers have made every effort to trace the copyright holders for borrowed material. If they have inadvertently overlooked any, they will be pleased to make the necessary arrangements at the first opportunity.

The great tragedy of science:
The slaying of a beautiful hypothesis by an ugly fact
Thomas Huxley (1825-1895)

ISBN 0-9546956-8-2

LAY-OUT: Stéphanie Taïeb

## **FOREWORD**

The First International Consultation on Incontinence held in 1998 highlighted the plight of some 200 millions sufferers from urinary incontinence worldwide. Urinary incontinence represents a particular and severe problem in certain developing areas of the world, where labour and birth injuries lead to catastrophic leakage. Untreated vesico-vaginal fistula (VVF), particularly in sub Saharan Africa, affects millions of women causing ostracism from society. Because of the enormity of this particular problem, at the second consultation we added a specific committee to highlight the subject, to advance the understanding of the causes of birth injury, to lead to improved treatment for the many untreated women, and most importantly, to begin preventative programmes. At this Fourth Consultation we were delighted by the active participation of the WHO in our work on VVF.

There were two other new committees in the 2nd ICI: Pelvic Organ Prolapse and Faecal Incontinence. The first consultation stressed the importance of a multidisciplinary approach to continence care, and the new committees on pelvic organ prolapse and faecal incontinence recognize that, particularly in women, urinary incontinence coexists with prolapse and faecal incontinence in many instances. This is also true, to a more limited extent, in men with coexisting faecal incontinence. The task of these two committees was very considerable and they had to outline the basic science, and investigation and management techniques within a single chapter. The report of these two chapters laid the foundation for a broadening of the multidisciplinary approach to pelvic disorders which was further developed in the 3<sup>rd</sup> ICI and now in the 4<sup>th</sup> ICI. New patterns by which care is delivered are emerging and depend on the close collaboration between urologists, gynaecologists and coloproctologists, working within a multidisciplinary team with nurses and physiotherapists. From the research and investigation point of view, we are very dependent on our colleagues from other disciplines such as the basic sciences, epidemiology, social science and engineering.

The 4<sup>th</sup> Consultation on Incontinence was held in Paris in July 2008. In this consultation we gave a special attention the VV fistula in the developing world in collaboration with the WHO and many other associations working in this field. The structure of the consultation followed the successful formula developed by the ICUD and used for the previous 3 consultations. Once again an international faculty of over 150 individuals from a wide range of professions and specialities were grouped into a series of subcommittees, each with a specific area of responsibility. The spectrum of subcommittees spanned from Basic Science through assessment and investigation to therapy. These committees were further divided into specific patient groups for children, women, men, neurological patients and the frail elderly. In addition to fully integrating faecal incontinence and pelvic organ prolapse into the consultation, there was the renamed committee "Bladder Pain Syndrome".

Subcommittee members were selected according to their academic reputation giving due recognition to the need to provide balance between specialities and geographical regions. A chairperson was selected for each subcommittee and was responsible for the drafting of that committees' chapter. Most committees met at least once before the consultation in Paris, to progress their report.

Each chairperson presented his or her committees' main discussions and recommendations in Paris. Their chapter was then modified accordingly, in the light of the consultation. This book details the evidence reviewed by each committee. Each committee used the ICUD System for evaluating evidence and providing recommendations with five levels of evidence (1 to 5) and four grades of recommendation (A to D).

This system worked well for the treatment committees but, as yet, it cannot be applied systematically to evaluate the evidence from the basic science and investigation committees. Nevertheless, the consultation feels that continued efforts to specify the evidence base for all recommendations are of vital importance.

The book's final chapter is the Recommendations of the International Scientific Committee which includes all subcommittee chairs together with the members of the Steering Committee. This chapter has been expanded to include algorithms for the treatment of faecal incontinence, pelvic organ prolapse and bladder pain syndrome. Furthermore, the 2004 algorithms have been reconfigured in the light of new evidence and in order to facilitate their use.

These recommendations represent the evidence based opinion of a group of experts. They are not to be considered as guidelines or standards of care which are the responsibility of official organisations, governments and regulators.

We hope that the huge amount of effort put into the consultation and the production of this book will also be reflected in an increased prominence for all aspects of the consultation's findings. We shall make the book more widely available and publish sections of the book in peer reviewed journals.

## Some of the members of the International



## **Committees Paris, France - July 5-8, 2008**



## **E**DITORS

- P. Abrams, U.K.
- L. Cardozo, U.K
- S. Khoury, France
- A. Wein USA

## MEMBERS OF THE COMMITTEES

(Alphabetical order - Chairmen in bold print)

1	ALTMAN	Daniel	Sweden	22	DEUTEKOM	Marije	The Netherlands
7	AMARENCO	Gerard	France	14	DMOCHOWSKI	Roger	USA
8	ANDERSSON	Karl Eric	Sweden	3	DRAKE	Marcus	UK
7	ARTIBANI	Walter	Italy	11	DUBEAU	Catherine	USA
5	AVERY	Kerry	UK	12	DUMOULIN	Chantale	Canada
18	BADLANI	gopal	USA	21	EE	Chyehua	Singapore
4	BAESSLER	Kaven	Germany	5	EMMANUEL	Anton	UK
7	BARTRAM	Clive	UK	20	FADER	Mandy	UK
12	BERGHMANS	Bary	The Netherlands	3	FOWLER	Clare	UK
3	BIRDER	Lori	USA	2	FRY	Chris	UK
16	BLISS	Donna Z.	USA	6	GAJEWSKI	Jerzy	Canada
20	BLISS	Donna Z.	USA	20	GETLIFFE	Katheryne	UK
5	BOSCH	Ruud	The Netherlands	15	GLAZENER	Charis	U.K
4	BOURCIER	Alain	France	21	GORDON	Barbara	Australia
9	BOWER	Wendy	Hong Kong	21	GORDON	Deborah	USA
23	BROWN	Jeanette	USA	21	GRIEBLING	T.	USA
18	BROWNING	Andrew	Ethiopia	3	GRIFFITHS	Derek	USA
15	BRUBAKER	Linda	USA	13	GRISE	Philippe	France
13	BRUSCHINI	Homero	Brazil	23	HAAB	François	France
20	BUCKLEY	Brian	Irland	12	HAGEN	Suzanne	UK
12	BURGIO	Kathryn	USA	8	HAMPEL	Christian	Germany
21	CAHILL	Barry	Australia	19	HANNO	Philip	USA
9	CANNING	Dough	USA	13	HANUS	Tomas	Czech Republic
6	CAPEWELL	Ann	UK	11	HARARI	Danielle	UK
8	CARDOZO	Linda	UK	16	HARARI	Danielle	UK
10	CASTRO	David	Spain	8	HASHIM	H.	U.K.
23	CASTRO	David	Spain	22	HAWTHORNE	Graeme	Australia
14	CHANG	Debuene	USA	12	HAY SMITH	Jean	New Zealand
8	CHAPPLE	Chris	UK	1	HERBISON	Peter	New Zeland
14	CHARTIER KASTLER	Emmanuel	France	13	HERSCHORN	Sender	Canada
13	COMITER	Craig	USA	14	HILTON	Paul	UK
20	COTTENDEN	Alan	UK	5	HIRSCH	Mark	USA
5	COTTERIL	Nikki	UK	9	HOEBEKE	Piet	Belgium
13	COUR	Florence	France	6	HOSKER	Gordon	UK
5	COYNE	Karen	USA	22	HU	Teh-Wei	USA
8	CRUZ	Francisco	Portugal	10	IGAWA	Yasuhiko	Japan
23	DANESHGARI	Firouz	USA	23	IGAWA	Yasuhiko	Japan
7	DE GENNARO	M.	Italy	15	JACQUETIN	Bernard	France
3	DE GROAT	Chet	USA	11	JOHNSON	Ted	USA
18	DE RIDDER	Dirk	Belgium	2	KANAI	Tony	USA
7	DELANCEY	John	USA	4	KARRAM	Mickey	U.K.

_	VELLEUED	0	LIIZ	4.5		NI.	lucalita.
5 7	KELLEHER	Con	UK UK	15	RAJAMAHESWARI		India
13	KHULLAR	Vik		19	RATNER	Vicki	USA
	KIRSCHNER-HERN		Germany The Nother deaders	6	ROBAIN	Gilberte	France
7	KLUIVERS	K	The Netherlands	2	ROOSEN	A.	Germany
4	KOELBL	Heinz	Germany	23	RORTVEIT	Guri	Norway
5	KOPP	Z.	USA The site and	6	ROSIER	Peter	The Netherlands
10	KOVINDHA	Apichana	Thailand	14	ROVNER	Eric	USA
11	KUCHEL	George A.	USA	10	RUFFION	Alain	France
23	KUSEK	John	USA	10	SAKAKIBARA	Ryuji	Japan
16	LANG	Julie	UK	4	SALVATORE	Stefano	Italy
1	LAPITAN	Marie Carmela		6	SAND	Peter K	USA
17	LAURBERG	Soren	Denmark	10	SCHURCH	Brigitte	Switzerland
19	LIN	Alex Tong-Long		1	SILLEN	Ulla	Sweden
10	MADERSBACHER		Austria	18	SINGH	P.B.	India
17	MADOFF	Robert	USA	14	SMITH	Tony	UK
15	MAHER	Christopher	Australia	18	SOMBIE	Issiaka	Burkina Faso
17	MATZEL	Klaus	Germany	21	SRINI	Vasan Satya	India
3	MAYER	Emeran	USA	5	STASKIN	David	USA
15	MELGREM	Α.	USA	2	STEERS	William	USA
17	MELLGREN	Anders	USA	23	STOTHERS	Mary-Ann Lynn	Canada
8	MICHEL	Martin	The Netherlands	22	SUBAK	leslee	USA
3	MILLS	lan	UK	4	SULTAN	Abdul	UK
1	MILSOM	lan	Sweden	6	SZABO	Laszlo	Hungary
17	MIMURA	Toshiki	Japan	2	TAKEDA	Masayuki	Japan
12	MOORE	Katherine	Canada	8	TANNENBAUM	Cara	Canada
22	MOORE	Kate	Australie	9	TEKGUL	Serdar	Turkey
3	MORRISON	John	U A Emirates			Oordar	rankoy
				1	THOM	David H	LISA
12	N'DOW	James	UK	1	THOR	David H.	USA
12 1	NELSON	James Richard	UK U.K.	3	THOR	Karl	USA
12 1 <b>21</b>	NELSON NEWMAN	James Richard <b>Diane</b>	UK U.K. <b>USA</b>	3 <b>7</b>	THOR TUBARO	Karl Andrea	USA Italy
12 1 <b>21</b> 9	NELSON NEWMAN NIJMAN	James Richard <b>Diane</b> Rien	UK U.K. <b>USA</b> The Netherlands	3 <b>7</b> 19	THOR TUBARO UEDA	Karl <b>Andrea</b> Tomohiro	USA Italy Japon
12 1 <b>21</b> 9 14	NELSON NEWMAN NIJMAN NILSSON	James Richard <b>Diane</b> Rien Karl Gustav	UK U.K. <b>USA</b> The Netherlands Finland	3 7 19 23	THOR TUBARO UEDA VAN KERREBOREO	Karl <b>Andrea</b> Tomohiro CK Philip	USA Italy Japon The Netherlands
12 1 <b>21</b> 9 14 21	NELSON NEWMAN NIJMAN NILSSON NISHIMURA	James Richard <b>Diane</b> Rien Karl Gustav Kaoru	UK U.K. <b>USA</b> The Netherlands Finland Japan	3 7 19 23 19	THOR TUBARO UEDA VAN KERREBOREO VAN OPHOREN	Karl Andrea Tomohiro CK Philip Arndt	USA Italy Japon The Netherlands Germany
12 1 <b>21</b> 9 14 21 4	NELSON NEWMAN NIJMAN NILSSON NISHIMURA NITTI	James Richard <b>Diane</b> Rien Karl Gustav	UK U.K. USA The Netherlands Finland Japan USA	3 7 19 23 19	THOR TUBARO UEDA VAN KERREBOREO VAN OPHOREN VARMA	Karl Andrea Tomohiro CK Philip Arndt Mika	USA Italy Japon The Netherlands Germany USA
12 1 21 9 14 21 4 19	NELSON NEWMAN NIJMAN NILSSON NISHIMURA NITTI NORDLING	James Richard Diane Rien Karl Gustav Kaoru Victor Jorgen	UK U.K. USA The Netherlands Finland Japan USA Denmark	3 7 19 23 19 17 7	THOR TUBARO UEDA VAN KERREBOREO VAN OPHOREN VARMA VIERHOUT	Karl Andrea Tomohiro CK Philip Arndt Mika M.E.	USA Italy Japon The Netherlands Germany USA The Netherlands
12 1 21 9 14 21 4 19 15	NELSON NEWMAN NIJMAN NILSSON NISHIMURA NITTI NORDLING NORTON	James Richard Diane Rien Karl Gustav Kaoru Victor Jorgen Peggy	UK U.K. USA The Netherlands Finland Japan USA Denmark USA	3 7 19 23 19 17 7	THOR TUBARO UEDA VAN KERREBOREO VAN OPHOREN VARMA VIERHOUT VODUSEK	Karl Andrea Tomohiro CK Philip Arndt Mika M.E. David	USA Italy Japon The Netherlands Germany USA The Netherlands Slovenia
12 1 21 9 14 21 4 19 15 16	NELSON NEWMAN NIJMAN NILSSON NISHIMURA NITTI NORDLING NORTON NORTON	James Richard Diane Rien Karl Gustav Kaoru Victor Jorgen Peggy Christine	UK U.K. USA The Netherlands Finland Japan USA Denmark USA UK	3 7 19 23 19 17 7 7	THOR TUBARO UEDA VAN KERREBOREO VAN OPHOREN VARMA VIERHOUT VODUSEK VON GONTHARD	Karl Andrea Tomohiro CK Philip Arndt Mika M.E. David Alexander	USA Italy Japon The Netherlands Germany USA The Netherlands Slovenia Germany
12 1 21 9 14 21 4 19 15 16 21	NELSON NEWMAN NIJMAN NILSSON NISHIMURA NITTI NORDLING NORTON NORTON	James Richard Diane Rien Karl Gustav Kaoru Victor Jorgen Peggy Christine Nancy	UK U.K. USA The Netherlands Finland Japan USA Denmark USA UK USA	3 7 19 23 19 17 7 7 9 15	THOR TUBARO UEDA VAN KERREBOREO VAN OPHOREN VARMA VIERHOUT VODUSEK VON GONTHARD VON THEOBALD	Karl Andrea Tomohiro CK Philip Arndt Mika M.E. David Alexander Peter	USA Italy Japon The Netherlands Germany USA The Netherlands Slovenia Germany France
12 1 21 9 14 21 4 19 15 16 21 19	NELSON NEWMAN NIJMAN NILSSON NISHIMURA NITTI NORDLING NORTON NORTON NORTON NYBERG	James Richard Diane Rien Karl Gustav Kaoru Victor Jorgen Peggy Christine Nancy Leroy	UK U.K. USA The Netherlands Finland Japan USA Denmark USA UK USA USA	3 7 19 23 19 17 7 7 9 15	THOR TUBARO UEDA VAN KERREBOREO VAN OPHOREN VARMA VIERHOUT VODUSEK VON GONTHARD VON THEOBALD WAGG	Karl Andrea Tomohiro CK Philip Arndt Mika M.E. David Alexander Peter Adrian	USA Italy Japon The Netherlands Germany USA The Netherlands Slovenia Germany France UK
12 1 21 9 14 21 4 19 15 16 21 19 12	NELSON NEWMAN NIJMAN NILSSON NISHIMURA NITTI NORDLING NORTON NORTON NORTON NYBERG NYGAARD	James Richard Diane Rien Karl Gustav Kaoru Victor Jorgen Peggy Christine Nancy Leroy Ingrid	UK U.K. USA The Netherlands Finland Japan USA Denmark USA UK USA USA USA	3 7 19 23 19 17 7 7 9 15 11	THOR TUBARO UEDA VAN KERREBOREO VAN OPHOREN VARMA VIERHOUT VODUSEK VON GONTHARD VON THEOBALD WAGG WAGNER	Karl Andrea Tomohiro CK Philip Arndt Mika M.E. David Alexander Peter Adrian Todd	USA Italy Japon The Netherlands Germany USA The Netherlands Slovenia Germany France UK USA
12 1 21 9 14 21 4 19 15 16 21 19 12	NELSON NEWMAN NIJMAN NILSSON NISHIMURA NITTI NORDLING NORTON NORTON NORTON NYBERG NYGAARD OCONNELL	James Richard Diane Rien Karl Gustav Kaoru Victor Jorgen Peggy Christine Nancy Leroy Ingrid Ronan	UK U.K. USA The Netherlands Finland Japan USA Denmark USA UK USA USA USA USA USA IRLAND	3 7 19 23 19 17 7 7 9 15 11 22 18	THOR TUBARO UEDA VAN KERREBOREO VAN OPHOREN VARMA VIERHOUT VODUSEK VON GONTHARD VON THEOBALD WAGG WAGNER WALL	Karl Andrea Tomohiro CK Philip Arndt Mika M.E. David Alexander Peter Adrian Todd Lewis	USA Italy Japon The Netherlands Germany USA The Netherlands Slovenia Germany France UK USA USA
12 1 21 9 14 21 4 19 15 16 21 19 12 17	NELSON NEWMAN NIJMAN NILSSON NISHIMURA NITTI NORDLING NORTON NORTON NORTON NYBERG NYGAARD OCONNELL PALMER	James Richard Diane Rien Karl Gustav Kaoru Victor Jorgen Peggy Christine Nancy Leroy Ingrid Ronan Mary	UK U.K. USA The Netherlands Finland Japan USA Denmark USA UK USA	3 7 19 23 19 17 7 7 9 15 11 22 18 15	THOR TUBARO UEDA VAN KERREBOREO VAN OPHOREN VARMA VIERHOUT VODUSEK VON GONTHARD VON THEOBALD WAGG WAGNER WALL WANG	Karl Andrea Tomohiro CK Philip Arndt Mika M.E. David Alexander Peter Adrian Todd Lewis Alex	USA Italy Japon The Netherlands Germany USA The Netherlands Slovenia Germany France UK USA USA Taiwan
12 1 21 9 14 21 4 19 15 16 21 19 12 17 11 20	NELSON NEWMAN NIJMAN NIJMAN NILSSON NISHIMURA NITTI NORDLING NORTON NORTON NORTON NORTON NYBERG NYGAARD OCONNELL PALMER PATERSON	James Richard Diane Rien Karl Gustav Kaoru Victor Jorgen Peggy Christine Nancy Leroy Ingrid Ronan Mary Jan	UK U.K. USA The Netherlands Finland Japan USA Denmark USA UK USA USA USA USA USA IRLAND USA Australia	3 7 19 23 19 17 7 7 9 15 11 22 18 15 8	THOR TUBARO UEDA VAN KERREBOREO VAN OPHOREN VARMA VIERHOUT VODUSEK VON GONTHARD VON THEOBALD WAGG WAGNER WALL WANG WEIN	Karl Andrea Tomohiro CK Philip Arndt Mika M.E. David Alexander Peter Adrian Todd Lewis Alex Alan	USA Italy Japon The Netherlands Germany USA The Netherlands Slovenia Germany France UK USA USA USA Taiwan USA
12 1 21 9 14 21 4 19 15 16 21 19 12 17	NELSON NEWMAN NIJMAN NIJMAN NILSSON NISHIMURA NITTI NORDLING NORTON NORTON NORTON NORTON NYBERG NYGAARD OCONNELL PALMER PATERSON PATON	James Richard Diane Rien Karl Gustav Kaoru Victor Jorgen Peggy Christine Nancy Leroy Ingrid Ronan Mary Jan Julian	UK U.K. USA The Netherlands Finland Japan USA Denmark USA UK USA USA USA USA USA IRLAND USA Australia UK	3 7 19 23 19 17 7 7 9 15 11 22 18 15 8 16	THOR TUBARO UEDA VAN KERREBOREO VAN OPHOREN VARMA VIERHOUT VODUSEK VON GONTHARD VON THEOBALD WAGG WAGNER WALL WANG WEIN WHITEHEAD	Karl Andrea Tomohiro CK Philip Arndt Mika M.E. David Alexander Peter Adrian Todd Lewis Alex Alan William	USA Italy Japon The Netherlands Germany USA The Netherlands Slovenia Germany France UK USA USA Taiwan USA USA
12 1 21 9 14 21 4 19 15 16 21 19 12 17 11 20 3 23	NELSON NEWMAN NIJMAN NIJMAN NILSSON NISHIMURA NITTI NORDLING NORTON NORTON NORTON NORTON NYBERG NYGAARD OCONNELL PALMER PATERSON PATON PAYNE	James Richard Diane Rien Karl Gustav Kaoru Victor Jorgen Peggy Christine Nancy Leroy Ingrid Ronan Mary Jan Julian Chris	UK U.K. USA The Netherlands Finland Japan USA Denmark USA UK USA USA USA IRLAND USA Australia UK USA	3 7 19 23 19 17 7 7 9 15 11 22 18 15 8 16 20	THOR TUBARO UEDA VAN KERREBOREO VAN OPHOREN VARMA VIERHOUT VODUSEK VON GONTHARD VON THEOBALD WAGG WAGNER WALL WANG WEIN WHITEHEAD WILDE	Karl Andrea Tomohiro CK Philip Arndt Mika M.E. David Alexander Peter Adrian Todd Lewis Alex Alan William Mary	USA Italy Japon The Netherlands Germany USA The Netherlands Slovenia Germany France UK USA USA Taiwan USA USA USA USA
12 1 9 14 21 4 19 15 16 21 17 11 20 3 23 19	NELSON NEWMAN NIJMAN NIJMAN NILSSON NISHIMURA NITTI NORDLING NORTON NORTON NORTON NORTON NYBERG NYGAARD OCONNELL PALMER PATERSON PATON PAYNE PAYNE	James Richard Diane Rien Karl Gustav Kaoru Victor Jorgen Peggy Christine Nancy Leroy Ingrid Ronan Mary Jan Julian	UK U.K. USA The Netherlands Finland Japan USA Denmark USA UK USA	3 7 19 23 19 17 7 7 7 9 15 11 22 18 15 8 16 20 21	THOR TUBARO UEDA VAN KERREBOREO VAN OPHOREN VARMA VIERHOUT VODUSEK VON GONTHARD VON THEOBALD WAGG WAGNER WALL WANG WEIN WHITEHEAD WILDE WILLIAMS	Karl Andrea Tomohiro CK Philip Arndt Mika M.E. David Alexander Peter Adrian Todd Lewis Alex Alan William Mary Kate	USA Italy Japon The Netherlands Germany USA The Netherlands Slovenia Germany France UK USA USA Taiwan USA USA USA USA USA USA USA
12 1 21 9 14 21 4 19 15 16 21 19 12 17 11 20 3 23	NELSON NEWMAN NIJMAN NIJMAN NILSSON NISHIMURA NITTI NORDLING NORTON NORTON NORTON NORTON NYBERG NYGAARD OCONNELL PALMER PATERSON PATON PAYNE PAYNE PERKASH	James Richard Diane Rien Karl Gustav Kaoru Victor Jorgen Peggy Christine Nancy Leroy Ingrid Ronan Mary Jan Julian Chris L.	UK U.K. USA The Netherlands Finland Japan USA Denmark USA UK USA USA USA IRLAND USA Australia UK USA	3 7 19 23 19 17 7 7 7 9 15 11 22 18 15 8 16 20 21 2	THOR TUBARO UEDA VAN KERREBOREO VAN OPHOREN VARMA VIERHOUT VODUSEK VON GONTHARD VON THEOBALD WAGG WAGNER WALL WANG WEIN WHITEHEAD WILLIAMS WOOD	Karl Andrea Tomohiro CK Philip Arndt Mika M.E. David Alexander Peter Adrian Todd Lewis Alex Alan William Mary Kate Dan	USA Italy Japon The Netherlands Germany USA The Netherlands Slovenia Germany France UK USA
12 1 21 9 14 21 4 19 15 16 21 17 11 20 3 23 19 10 11	NELSON NEWMAN NIJMAN NIJMAN NILSSON NISHIMURA NITTI NORDLING NORTON NORTON NORTON NORTON NYBERG NYGAARD OCONNELL PALMER PATERSON PATON PAYNE PAYNE PERKASH PFISTERER	James Richard Diane Rien Karl Gustav Kaoru Victor Jorgen Peggy Christine Nancy Leroy Ingrid Ronan Mary Jan Julian Chris Chris	UK U.K. USA The Netherlands Finland Japan USA Denmark USA UK USA USA USA IRLAND USA Australia UK USA USA USA Germany	3 7 19 23 19 17 7 7 9 15 11 22 18 15 8 16 20 21 2	THOR TUBARO UEDA VAN KERREBOREO VAN OPHOREN VARMA VIERHOUT VODUSEK VON GONTHARD VON THEOBALD WAGG WAGNER WALL WANG WEIN WHITEHEAD WILLIAMS WOOD WYNDAELE	Karl Andrea Tomohiro CK Philip Arndt Mika M.E. David Alexander Peter Adrian Todd Lewis Alan William Mary Kate Dan Jean Jacques	USA Italy Japon The Netherlands Germany USA The Netherlands Slovenia Germany France UK USA USA Taiwan USA USA USA USA USA USA USA
12 1 21 9 14 21 4 19 15 16 21 17 11 20 3 23 19 10	NELSON NEWMAN NIJMAN NIJMAN NILSSON NISHIMURA NITTI NORDLING NORTON NORTON NORTON NORTON NYBERG NYGAARD OCONNELL PALMER PATERSON PATON PAYNE PAYNE PERKASH PFISTERER PIETERS	James Richard Diane Rien Karl Gustav Kaoru Victor Jorgen Peggy Christine Nancy Leroy Ingrid Ronan Mary Jan Julian Chris Chris I. Mathias Ronny	UK U.K. USA The Netherlands Finland Japan USA Denmark USA UK USA USA USA IRLAND USA Australia UK USA USA Germany Belgium	3 7 19 23 19 17 7 7 7 9 15 11 22 18 15 8 16 20 21 2	THOR TUBARO UEDA VAN KERREBOREO VAN OPHOREN VARMA VIERHOUT VODUSEK VON GONTHARD VON THEOBALD WAGG WAGNER WALL WANG WEIN WHITEHEAD WILDE WILLIAMS WOOD WYNDAELE YAMAGUCHI	Karl Andrea Tomohiro CK Philip Arndt Mika M.E. David Alexander Peter Adrian Todd Lewis Alax Alan William Mary Kate Dan Jean Jacques Osamu	USA Italy Japon The Netherlands Germany USA The Netherlands Slovenia Germany France UK USA USA Taiwan USA
12 1 21 9 14 21 4 19 15 16 21 17 11 20 3 23 19 10 11	NELSON NEWMAN NIJMAN NIJMAN NILSSON NISHIMURA NITTI NORDLING NORTON NORTON NORTON NORTON NYBERG NYGAARD OCONNELL PALMER PATERSON PATON PAYNE PAYNE PERKASH PFISTERER	James Richard Diane Rien Karl Gustav Kaoru Victor Jorgen Peggy Christine Nancy Leroy Ingrid Ronan Mary Jan Julian Chris Chris I. Mathias	UK U.K. USA The Netherlands Finland Japan USA Denmark USA UK USA USA USA IRLAND USA Australia UK USA USA USA Germany	3 7 19 23 19 17 7 7 9 15 11 22 18 15 8 16 20 21 2	THOR TUBARO UEDA VAN KERREBOREO VAN OPHOREN VARMA VIERHOUT VODUSEK VON GONTHARD VON THEOBALD WAGG WAGNER WALL WANG WEIN WHITEHEAD WILLIAMS WOOD WYNDAELE	Karl Andrea Tomohiro CK Philip Arndt Mika M.E. David Alexander Peter Adrian Todd Lewis Alan William Mary Kate Dan Jean Jacques	USA Italy Japon The Netherlands Germany USA The Netherlands Slovenia Germany France UK USA USA Taiwan USA

## **M**EMBERS OF THE **C**OMMITTEES (by Committee)

1. Epidemiology			ROBAIN	Gilberte	France
ALTMAN	Daniel	Sweden	ROSIER	Peter	The Netherlands
HERBISON	Peter	New Zeland	SAND	Peter K	USA
LAPITAN	Marie C.	Philippines	SZABO	Laszlo	Hungary
MILSOM	lan	Sweden	7. Imaging, Neurop		
NELSON	Richard	U.K.	AMARENCO	Gerard	France
SILLEN	Ulla	Sweden	ARTIBANI	Walter	Italy
THOM	David H.	USA	BARTRAM	Clive	UK
2. Cell Biology			DE GENNARO	M.	Italy
FRY	Chris	UK	DELANCEY	John	USA
KANAI	Tony	USA	KHULLAR	Vik	UK
STEERS	William	USA	KLUIVERS	K	The Netherlands
TAKEDA	Masayuki	Japan	PODNAR	S.	Slovenia
ROOSEN	A.	Germany	TUBARO	Andrea	Italy
STEERS	William	USA	VIERHOUT	M.E.	The Netherlands
TAKEDA	Masayuki	Japan	VODUSEK	David	Slovenia
WOOD	Dan	UK			
0.11 1.0 ( )			8. Drug Treatment	Kaul Eula	Curadan
3. Neural Control	1.00	1104	ANDERSSON	Karl Eric	Sweden
BIRDER	Lori	USA	CARDOZO	Linda	UK UK
DE GROAT	Chet	USA	CHAPPLE	Chris	
DRAKE	Marcus	UK	CRUZ	Francisco	Portugal
FOWLER	Clare	UK	HAMPEL	Christian	Germany
GRIFFITHS	Derek	USA	HASHIM	H.	U.K.
MAYER	Emeran	USA UK	MICHEL	Martin	The Netherlands
MILLS MORRISON	lan John	Arab Emrates	TANNENBAUM	Cara	Canada
PATON	Julian	UK	WEIN	Alan	USA
THOR	Karl	USA	9. Children		
MOR	Naii	USA	BOWER	Wendy	Hong Kong
4. Pathophysiology	1		CANNING	Dough	USA
BAESSLER	Kaven	Germany	HOEBEKE	Piet	Belgium
BOURCIER	Alain	France	NIJMAN	Rien	The Netherlands
KARRAM	Mickey	U.K.	TEKGUL	Serdar	Turkey
KOELBL	Heinz	Germany	<b>VON GONTHARD</b>	Alexander	Germany
NITTI	Victor	USA	10. Neurogenic Pat	tients	
SALVATORE	Stefano	Italy	CASTRO	David	Spain
SULTAN	Abdul	UK	IGAWA	Yasuhiko	Japan
YAMAGUCHI	Osamu	Japan	KOVINDHA	Apichana	Thailand
5. Initial Assessme	nt Including	Quality of Life	MADERSBACHER	Helmut	Austria
AVERY	Kerry	UK	PERKASH	I.	USA
BOSCH	Ruud	The Netherlands	RADZISZEWSKI	Piotr	Poland
COTTERIL	Nikki	UK	RUFFION	Alain	France
COYNE	Karen	USA	SAKAKIBARA	Ryuji	Japan
EMMANUEL	Anton	UK	SCHURCH	Brigitte	Switzerland
HIRSCH	Mark	USA	WYNDAELE	J-Jacques	Belgium
KELLEHER	Con	UK	11. Frail Elderly		
KOPP	Z.	USA	DUBEAU	Catherine	USA
STASKIN	David	USA	HARARI	Danielle	UK
YOSHIDA	Masaki	Japan	JOHNSON	Ted	USA
6. Dynamic Testing			KUCHEL	George A.	USA
CAPEWELL	Ann	UK	PALMER	Mary	USA
GAJEWSKI	Jerzy	Canada	PFISTERER	Mathias	Germany
HOSKER	Gordon	UK	WAGG	Adrian	UK

**BERGHMANS** The Netherlands Bary **USA BURGIO** Kathryn Chantale **DUMOULIN** Canada Suzanne UK **HAGEN** Jean **New Zealand HAY SMITH** 

**MOORE** Katherine Canada N'DOW **James** UK **NYGAARD** Ingrid **USA** 

#### 13. Surgery for Urinary Incontinence in Men

**BRUSCHINI** Homero Brazil **COMITER** Craig **USA COUR Florence** France **GRISE Philippe** France

**HANUS Tomas** Czech Republic **HERSCHORN** Sender Canada KIRSCHNER-HERMANNS Ruth Germany

#### 14. Surgery for Urinary Incontinence In Women

**CHANG** Debuene USA CHARTIER KASTLER Emmanuel France **DMOCHOWSKI USA** Roger HILTON Paul UK **NILSSON** Karl Gustav Finland Eric USA **ROVNER SMITH Tony** UK

#### 15. Surgery for Pelvic Organ Prolapse

**USA BRUBAKER** Linda Charis U.K **GLAZENER JACQUETIN** Bernard France **MAHER** Christopher Australia **USA MELGREM NORTON** Peggy **USA RAJAMAHESWARI** India N. **VON THEOBALD** Peter France Taiwan WANG Alex

#### 16. Conservative Treatment for Faecal Incontinence

**BLISS** Donna Z. **USA HARARI** Danielle UK LANG Julie UK **NORTON Christine** UK WHITEHEAD William USA

#### 17. Surgery for Faecal Incontinence

**LAURBERG** Soren Denmark **MADOFF USA** Robert Klaus Germany **MATZEL MELLGREN Anders USA MIMURA** Toshiki Japan O'CONNELL Ronan Irland Mika **USA VARMA** 

#### 18. Vesico-Vaginal Fistulas in the Developing World

**BADLANI** gopal **USA BROWNING** Andrew Ethiopia **DE RIDDER** Dirk **Belgium**  SINGH P.B. India **SOMBIE** Issiaka Burkina Faso **USA** WALL Lewis

#### 19. Painful Bladder Syndrome

**HANNO Philip USA** LIN A.Tong-Long Taiwan **NORDLING** Jorgen Denmark USA **NYBFRG** Leroy **PAYNE** Chris USA RATNER Vicki **USA UEDA Tomohiro** Japon VAN OPHOREN Arndt Germany

#### 20. Technical Aspects of Continence Devices

**BLISS** Donna Z. **USA BUCKLEY** Brian Irland **COTTENDEN** Alan UK UK **FADER** Mandy UK **GETLIFFE** Kathervne **PATERSON** Jan Australia **PIETERS** Ronny Belgium **WILDE USA** Mary

#### 21. Education and Continence Promotion

**CAHILL** Australia Barry EE Chyehua Singapore **GORDON** Barbara Australia **GORDON** Deborah **USA GRIEBLING** T. **USA NEWMAN Diane USA NISHIMURA** Kaoru Japan Nancy **NORTON USA** SRINI Vasan Satva India **WILLIAMS** Kate UK

#### 22. Economics of Incontinence


**DEUTEKOM** The Netherlands Marije **HAWTHORNE** Graeme Australia HU Teh-Wei **USA MOORE** Kate Australia **SUBAK** leslee **USA WAGNER** Todd USA

#### 23. Research

**BROWN** USA **Jeanette CASTRO** David Spain **DANESHGARI Firouz** USA HAAB François France **IGAWA** Yasuhiko Japan **KUSEK** John **USA PAYNE Chris USA** Norway **RORTVEIT** Guri **STOTHERS** Mary-Ann L. Canada

VAN KERREBORECK Philip The Netherlands

ZIMMERN **Philippe** USA



Professor William C de GROAT Ph. D. President

4<sup>th</sup> International Consultation on Incontience

Dr. William C. de Groat is Professor of Pharmacology at the University of Pittsburgh Medical School. He received a Ph.D. in Pharmacology from the University of Pennsylvania Medical School in 1965 and then obtained postdoctoral training in Pharmacology at the University of Pennsylvania (1965-1966) and in Neurophysiology at the John Curtin School for Medical Research in Canberra, Australia (1966-1968).

He joined the faculty at the University of Pittsburgh in 1968 and was promoted to Professor in 1977. He has been a Visiting Scientist at the NIH (1988-1989) and at the University College London (1998).

Dr. de Groat is a member of various societies including the American Society for Pharmacology and Experimental Therapeutics, Society for Neuroscience, The American Autonomic Society, International Society for Autonomic Neuroscience, International Continence Society, International Spinal Cord Society, Society for Urodynamics and Female Urology, Society for Basic Urologic Research, American Motility Society, The Dana Alliance for Brain Initiatives.

He is an Honorary Member of the American Urological Association and the Japanese Urological Association. Dr. de Groat has published more than 400 papers primarily in the fields of autonomic neuroscience and neurourology. He has served on numerous editorial boards including: *The Journal of Pharmacology and Experimental Therapeutics, American Journal of Physiology, Urology, Neurourology and Urodynamics, Autonomic Neuroscience, and Life Sciences*.

Dr. de Groat has been Treasurer and a member of the Executive Council of the Society for Neuroscience and the Executive Vice President of the International Society for Autonomic Neuroscience. He is the recipient of a number of awards including: a National Institutes of Health (NIH) Method to Extend Research in Time (MERIT) Award, an NIH Research Career Development Award, a Lifetime Achievement Award from the Urodynamics Society and a Fellow of the American Association for Advancement of Science.

He has been recognized with the Carl Ludwig Distinguished Lectureship of the American Physiological Society, the University of Pittsburgh President's Distinguished Research Award, the Pharmacia-ASPET Award for Experimental Therapeutics from the American Society for Pharmacology and Experimental Therapeutics, the Elsevier-JANS Lectureship of the International Society for Autonomic Neuroscience, the Sir Ludwig Guttman Lectureship of the International Society of Paraplegia and the University of Pittsburgh Chancellor's Distinguished Teaching Award.

SYNOPSIS OF AREA OF INTEREST: Dr. de Groat is interested in the neural control of the lower urinary tract and the mechanisms underlying urinary incontinence and painful bladder conditions.

## EVIDENCE – BASED MEDICINE OVERVIEW OF THE MAIN STEPS FOR DEVELOPING AND GRADING GUIDELINE RECOMMENDATIONS.

#### INTRODUCTION

The International Consultation on Urological Diseases (ICUD) is a non-governmental organization registered with the World Health Organisation (WHO). In the last ten years Consultations have been organised on BPH, Prostate Cancer, Urinary Stone Disease, Nosocomial Infections, Erectile Dysfunction and Urinary Incontinence. These consultations have looked at published evidence and produced recommendations at four levels; highly recommended, recommended, optional and not recommended. This method has been useful but the ICUD believes that there should be more explicit statements of the levels of evidence that generate the subsequent grades of recommendations.

The Agency for Health Care Policy and Research (AHCPR) have used specified evidence levels to justify recommendations for the investigation and treatment of a variety of conditions. The Oxford Centre for Evidence Based Medicine have produced a widely accepted adaptation of the work of AHCPR. (June 5th 2001 <a href="http://minerva.minervation.com/cebm/docs/levels.html">http://minerva.minervation.com/cebm/docs/levels.html</a>). The ICUD has examined the Oxford guidelines and discussed with the Oxford group their applicability to the Consultations organised by ICUD. It is highly desirable that the recommendations made by the Consultations follow an accepted grading system supported by explicit levels of evidence.

The ICUD proposes that future consultations should use a modified version of the Oxford system which can be directly 'mapped' onto the Oxford system.

- 1. 1st Step: Define the specific questions or statements that the recommendations are supposed to address.
- 2. 2nd Step: Analyse and rate (level of evidence) the relevant papers published in the literature.

The analysis of the literature is an important step in preparing recommendations and their guarantee of quality.

#### 2.1 What papers should be included in the analysis?

- Papers published, or accepted for publication in the peer reviewed issues of journals.
- The committee should do its best to search for papers accepted for publication by the peer reviewed journals in the relevant field but not yet published.
- Abstracts published in peer review journals should be identified. If of sufficient interest the author(s) should be asked for full details of methodology and results. The relevant committee members can then 'peer review' the data, and if the data confirms the details in the abstract, then that abstract may be included, with an explanatory footnote. This is a complex issue – it may actually increase publication bias as "uninteresting" abstracts commonly do not progress to full publication.
- Papers published in non peer reviewed supplements will not be included.

An exhaustive list should be obtained through:

- the major databases covering the last ten years (e.g. Medline, Embase, Cochrane Library, Biosis, Science Citation Index)
- II. the table of contents of the major journals of urology and other relevant journals, for the last three months, to take into account the possible delay in the indexation of the published papers in the databases.

It is expected that the highly experienced and expert committee members provide additional assurance that no important study would be missed using this review process.

#### 2.2 How papers are analysed?

Papers published in peer reviewed journals have differing quality and level of evidence.

Each committee will rate the included papers according to levels of evidence (see below).

The level (strength) of evidence provided by an individual study depends on the ability of the study design to minimise the possibility of bias and to maximise attribution. is influenced by:

#### the type of study

The hierarchy of study types are:

- Systematic reviews and meta-analysis of randomised controlled trials
- Randomised controlled trials
- Non-randomised cohort studies
- Case control studies
- Case series
- Expert opinion

#### how well the study was designed and carried out

Failure to give due attention to key aspects of study methodology increase the risk of bias or confounding factors, and thus reduces the study's reliability.

The use of **standard check lists** is recommended to insure that all relevant aspects are considered and that a consistent approach is used in the methodological assessment of the evidence.

The objective of the check list is to give a quality rating for individual studies.

#### how well the study was reported

The ICUD has adopted the CONSORT statement and its widely accepted check list. The CONSORT statement and the checklist are available at http://www.consort-statement.org

#### 2.3 How papers are rated?

Papers are rated following a « **Level of Evidence scale**». ICUD has modified the Oxford Center for Evidence-Based Medicine levels of evidence.

The levels of evidence scales vary between types of studies (ie therapy, diagnosis, differential diagnosis/symptom prevalence study).

the Oxford Center for Evidence-Based Medicine Website: http://minerva.minervation.com/cebm/docs/levels.html

#### 3. 3rd Step: Synthesis of the evidence

After the selection of the papers and the rating of the level of evidence of each study, the next step is to compile a summary of the individual studies and the overall direction of the evidence in an **Evidence Table**.

## 4. 4th Step: Considered judgment (integration of individual clinical expertise)

Having completed a rigorous and objective synthesis of the evidence base, the committee must then make a judgement as to the grade of the recommendation on the basis of this evidence. This requires the exercise of judgement based on clinical experience as well as knowledge of the evidence and the methods used to generate it. Evidence based medicine requires the integration of individual clinical expertise with best available external clinical evidence from systematic research. Without the former, practice quickly becomes tyrannised by evidence, for even excellent external evidence may be inapplicable to, or inappropriate for, an individual patient: without current best evidence, practice quickly becomes out of date. Although it is not practical to lay our "rules"

for exercising judgement, guideline development groups are asked to consider the evidence in terms of quantity, quality, and consistency; applicability; generalisability; and clinical impact.

#### 5. 5th Step: Final Grading

The grading of the recommendation is intended to strike an appropriate balance between incorporating the complexity of type and quality of the evidence and maintaining clarity for guideline users.

The recommendations for grading follow the Oxford Centre for Evidence-Based Medicine.

The levels of evidence shown below have again been modified in the light of previous consultations. There are now 4 levels of evidence instead of 5.

The grades of recommendation have not been reduced and a "no recommendation possible" grade has been added.

#### 6. Levels of Evidence and Grades of Recommendation Therapeutic Interventions

All interventions should be judged by the body of evidence for their efficacy, tolerability, safety, clinical effectiveness and cost effectiveness. It is accepted that at present little data exists on cost effectiveness for most interventions.

#### 6.1 Levels of Evidence

Firstly, it should be stated that any level of evidence may be positive (the therapy works) or negative (the therapy doesn't work). A level of evidence is given to each individual study.

- Level 1 evidence (incorporates Oxford 1a, 1b) usually involves meta-anaylsis of trials (RCTs) or a good quality randomised controlled trial, or 'all or none' studies in which no treatment is not an option, for example in vesicovaginal fistula.
- Level 2 evidence (incorporates Oxford 2a, 2b and 2c) includes "low" quality RCT (e.g. < 80% follow up) or meta-analysis (with homogeneity) of good quality prospective 'cohort studies'. These may include a single group when individuals who develop the condition are compared with others from within the original cohort group. There can be parallel cohorts, where those with the condition in the first group are compared with those in the second group.</li>
- Level 3 evidence (incorporates Oxford 3a, 3b and 4) includes:

good quality retrospective 'case-control studies' where a group of patients who have a condition are matched appropriately (e.g. for age, sex etc) with control individuals who do not have the condition.

good quality 'case series' where a complete group of patients all, with the same condition/disease/therapeutic intervention, are described, without a comparison control group.

 Level 4 evidence (incorporates Oxford 4) includes expert opinion were the pinion is based not on evidence but on 'first principles' (e.g. physiological or anatomical) or bench research. The Delphi process can be used to give 'expert opinion' greater authority. In the Delphi process a series of questions are posed to a panel; the answers are collected into a series of 'options'; the options are serially ranked; if a 75% agreement is reached then a Delphi consensus statement can be made.

#### 6.2 Grades of Recommendation

The ICUD will use the four grades from the Oxford system. As with levels of evidence the grades of evidence may apply either positively (do the procedure) or negatively (don't do the procedure). Where there is disparity of

evidence, for example if there were three well conducted RCT's indicating that Drug A was superior to placebo, but one RCT whose results show no difference, then there has to be an individual judgement as to the grade of recommendation given and the rationale explained.

- Grade A recommendation usually depends on consistent level 1 evidence and often means that the recommendation is effectively mandatory and placed within a clinical care pathway. However, there will be occasions where excellent evidence (level 1) does not lead to a Grade A recommendation, for example, if the therapy is prohibitively expensive, dangerous or unethical. Grade A recommendation can follow from Level 2 evidence. However, a Grade A recommendation needs a greater body of evidence if based on anything except Level 1 evidence
- Grade B recommendation usually depends on consistent level 2 and or 3 studies, or 'majority evidence' from RCT's.
- Grade C recommendation usually depends on level 4 studies or 'majority evidence' from level 2/3 studies or Dephi processed expert opinion.
- Grade D "No recommendation possible" would be used where the evidence is inadequate or conflicting and when expert opinion is delivered without a formal analytical process, such as by Dephi.
- 7. Levels of Evidence and Grades of Recommendation for Methods of Assessment and Investigation

From initial discussions with the Oxford group it is clear that application of levels of evidence/grades of recommendation for diagnostic techniques is much more complex than for interventions. The ICUD recommend, that, as a minimum, any test should be subjected to three questions:

- does the test have good technical performance, for example, do three aliquots of the same urine sample give the same result when subjected to 'stix' testing?
- 2. Does the test have good diagnostic performance, ideally against a "gold standard" measure?
- 3. Does the test have good therapeutic performance, that is, does the use of the test alter clinical management, does the use of the test improve outcome?

For the third component (therapeutic performance) the same approach can be used as for section 6.

 Levels of Evidence and Grades of Recommendation for Basic Science and Epidemiology Studies

The proposed ICUD system does not easily fit into these areas of science. Further research needs to be carried out, in order to develop explicit levels of evidence that can lead to recommendations as to the soundness of data in these important aspects of medicine.

#### CONCLUSION

The ICUD believes that its consultations should follow the ICUD system of levels of evidence and grades of recommendation, where possible. This system can be mapped to the Oxford system.

There are aspects to the ICUD system that require further research and development, particularly diagnostic performance and cost effectiveness, and also factors such as patient preference.

P. Abrams, S Khoury, A. Grant 19/1/04

## **C**ONTENTS

Foreword	3
Pr William C de GROAT - President	10
Levels of Evidence and Grades of Recommendation	12
A Brief history of urinary incontinence and its treatment Dirk Schultheiss (Germany)	19
Committee 1 : Epidemiology of Urinary (UI) and Faecal (FI) Incontinence and Pelvic Organ Prolapse (POP)  I. Milsom (Sweden) D. Altman (Sweden), M.C. Lapitan (The Philippines), R. Nelson (U.K), U. Sillén (Sweden), D. Thom (USA)	35
Committee 2 : Cell Biology C.H Fry (U.K), A.J Kanai (USA), A. Roosen (Germany), M. Takeda (Japan), D.N Wood (U.K)	113
Committee 3: Neural Control L. Birder (USA), M. Drake (UK), W. de Groat (USA), C. Fowler (U.K), E. Mayer (USA), J. Morrison (UAE), J. Paton (U.K) Consultants: D. Griffiths (Canada), I. Mills (U.K), K. Thor (USA)	167
Committee 4: Pathophysiology of Urinary Incontinence, Faecal Incontinence and Pelvic Organ Prolapse  H. Koelbl (Germany) V. Nitti (USA), K. Baessler (Germany), S. SAlvatore (Italy),  A. Sultan (U.K), O. Yamaguchi (Japan)	255
Committee 5 a: Initial Assessment of Urinary and Faecal Incontinence in Adult Male and Female Patients  D. Staskin (USA), C. Kelleher (U.K), K. Avery (U.K), R. Bosch (N.L), N. Cotterill (U.K), K. Coyne (USA), A. Emmanuel (U.K), M. Yoshida (Japan) Consultant: Z. Kopp (USA)  Committee 5 B: Patient-Reported Outcome Assessment	331 363
Committee 6: Dynamic Testing G. Hosker (U.K), P. Rosier (The Netherlands), J. Gajewski (Canada), P. Sand (USA) Consultants: L. Szabo (Hungary), A. Capewell (U.K)	413
Committee 7 A: Clinical neurophysiological Tests  D. Vodusek (Slovenia), G. Amarenco (France), S. Podnar (Slovenia)  Committee 7 B: Imaging and other Investigations  A. Tubaro (Italy), W. Artibani (Italy), C. Bartram (U.K), J. DeLancey (USA),  V. Khullar (U.K), M. Vierhout (The Netherlands)  Consultants: M. De Gennaro (Italy), K. Kluivers (The Netherlands)	523 541
Committee 8: Pharmacological Treatment of Urinary Incontinence Karl-Erik Andersson (USA), C. R Chapple (U.K), L. Cardozo (U.K), F. Cruz (Portugal), H. Hashim (U.K), M.C. Michel (The Netherlands), C. Tannenbaum (Canada), A.J. Wein (USA)	631
Committee 9: Diagnosis and management of urinary incontinence in childhood  S. Tekgul (Turkey), R. JM Nijman (The Netherlands), P. Hoebeke (Belgium), D. Canning (USA), W.Bower (Hong-Kong), A. von Gontard (Germany)	701
Committee 10: Neurologic Urinary and Faecal Incontinence  J.J. Wyndaele (Belgium), A. Kovindha (Thailand), H. Madersbacher (Austria),  P. Radziszewski (Poland), A. Ruffion (France), B. Schurch (Switzerland)  Consultants: D. Castro (Spain), Y. Igawa (Japan), R. Sakakibara (Japan)  Advisor: I. Perkash (USA)	793

Committee 11: Incontinence in the Frail Elderly C.E. DuBeau (USA), G.A. Kuchel (USA), T. Johnson (USA), M.H. Palmer (USA), A. Wagg (U.K)	961
Committee 12: Adult Conservative Management  J. Hay Smith (New Zeland), B. Berghmans (The Nederlands), K. Burgio (USA), C. Dumoulin (Canada), S. Hagen (U.K), K. Moore (Canada), I. Nygaard (USA)  Consultant: J. N'dow (U.K)	1025
Committee 13: Surgical Treatment of Urinary Incontinence in Men S. Herschorn (Canada), H. Bruschini (Brazil), C.Comiter (USA), P.Grise (France), T. Hanus (Czech Republic), R. Kirschner-Hermanns (Germany)	1121
Committee 14: Surgery for urinary incontinence in women T. Smith (U.K), D. Chang (U.K), R. Dmochowski (USA), P. Hilton (U.K), C.G Nilsson (Finland), F.M Reid (U.K), E. Rovner (USA)	1191
Committee 15 : Surgery for pelvic organ prolapse L. Brubaker (USA), C. Glazener (U.K), B. Jacquetin (France), C. Maher (Australia), A. Melgrem (USA), P. Norton (USA), N. Rajamaheswari (India), P. Von theobald (France)	1273
Committee 16: Conservative and Pharmacological Management of Faecal Incontinence in Adults  C. Norton (U.K), W.Whitehead (USA), D. Z Bliss (USA), D. Harari (U.K), J. Lang (U.K)	1321
Committee 17: Surgery for Faecal Incontinence R.D. Madoff (USA), S. Laurberg (Denmark), K.E. Matzel (Germany), A.F. Mellgren (USA), T. Mimura (Japan), P.R. O'Connell (Ireland), M.G. Varma (USA)	1387
Committee 18: Fistulas in the Developing World  D. De Ridder (Belgium), G. H. Badlani (USA), A. Browning (Ethiopia), P. Singh (India), I. Sombie (Burkina Faso), L. L. Wall (USA)	1419
Committee 19: Bladder Pain Syndrome P. Hanno (USA), A. Lin (Taiwan), J. Nordling (Denamark), L. Nyberg (USA), A. van Ophoven (Germany), T. Ueda (Japon)	1459
Committee 20: Management Using Continence Products  A. Cottenden (U.K), D.Z.Bliss (USA), B. Buckley (Irland), M. Fader (U.K), K. Getliffe (U.K), J. Paterson (Australia), R. Pieters (Belgium), M. Wilde (USA)	1519
Committee 21 : Continence Promotion, Education & Primary Prevention D. K. Newman (USA), C. H. Ee (Singapore), D. Gordon (Australia), V. S. Srini (India), K. Williams (U.K) Consultants : B. Cahill (Australia), B. Gordon (USA), T. Griebling (USA), K. Nishimura (Japan) N. Norton (USA)	1643
Committee 22: Economics of Urinary & Faecal Incontinence, and Prolapse K. Moore (Australia), T. Wei Hu (USA), L. Subak (USA), T. Wagner (USA), M. Deutekom (The Netherlands)	1685
Committee 23: Research C. Payne (USA), J. Brown (USA), D. Castro (Spain), F. Daneshgari (USA), F. Haab (France), Y. Igawa (Japan), J. Kusek (USA), G. Rortveit (Norway), M-A Stothers (Canada), P. Van Kerreboreck (The Netherlands), P. Zimmern (USA)	1713
Recommendations of the International Scientific Committee: Evaluation and Treatment of Urinary Incontinence, Pelvic Organ Prolapse and Faecal Incontinence	1767
Index	1821

## INCONTINENCE

## **EDITORS**

Paul Abrams - Linda Cardozo - Saad Khoury - Alan Wein